EMA Authorised: Inluriyo (imlunestrant tosilate) — Eli Lilly Nederland B.V.

View source ↗

Summary

EMA authorised Inluriyo (imlunestrant tosilate) for breast cancer, with Eli Lilly Nederland B.V. as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• INLURIYO (IMLUNESTRANT)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Eli Lilly Nederland B.V.. Decision date: 20/02/2026